The addition of polyethyleneglycol (PEG) side chains to interferon a-2a improves the serum stability and clinical efficacy. Current commercial PEG-INF formulations such as PEGASYS s are heterogeneous and contain multiple monopegylated isomers. We have analyzed the activity of nine, purified monopegylated variants in antiproliferative, antiviral and binding assays, together with a global transcriptional analysis using DNA oligonucleotide microarrays. We show a direct correlation between biological and transcriptional activity for all isomers and an inversed correlation between IFN-receptor 2a affinity and signal transduction. Two out of nine positional isomers have a higher specific biological and transcriptional activity than the mixture, which can be explained by unique structural features of interferon signaling, which involves two distinct receptors. The possible clinical implications are discussed, which might guide the development of pegylated interferons with improved pharmacological properties.
INTRODUCTION
In 1957, Isaacs and Lindenmann first described a glycoprotein, which they named 'interferon'. They showed that the interferons were produced in virally infected cells to protect them against further viral infection. 1 The interferons have since been classified into two types of categories on the basis of their immunological, biological and chemical properties: type I interferons include subtypes of interferon-a, -b, -o, -t, and type II interferons are subtypes of interferon-g. 2 Interferon a-2a (IFN) plays an important role in mediating antiviral and antiproliferative responses, and in modulating immune responses. These biological activities make IFN important as an inhibitor of disease pathogenesis and useful in the treatment of viral infections and some cancers. 3, 4 Since 1986, recombinant human IFN has become an important therapeutic agent to treat patients with viral and oncological diseases. The success of IFN treatment in the clinic is partly limited due to its short serum half-life of 4-6 h. Peak concentrations of IFN occur at 3-8 h following i.v. or s.c. administration, and large fluctuations in serum concentrations can occur after each dose. After 24 h, the amount of exogenous IFN remaining in the body is negligible, so that the thrice-weekly regimen used is unlikely to maintain concentrations required for antiviral activity.
The administration frequency of IFN is dependent on the disease progress. For example, the standard therapeutic application of IFN consists of three million international units administered subcutaneously three times per week for up to 48 weeks, while certain oncological indications may require daily administration.
More recently, it was found that the coupling of polyethyleneglycol to IFN improves the pharmacokinetic and pharmacodynamic properties of IFN, which led to the development of novel interferons. Since several years, studies were carried out to assess the influence of the various PEG chain lengths and PEG types on the bioactivity in vitro and in vivo. Branched PEG moieties, for instance, may more effectively cloak and protect IFN from proteolytic degradation than linear PEG chains, or else enhance the absorption and distribution properties of the protein. [7] [8] [9] It has further been demonstrated that high molecular weight PEG side chains decrease the serum clearance, thereby producing sustained exposure to the virus and higher antiviral activity. 10 These findings led to the development of a commercial formulation of pegylated interferon termed PEGASYS s . In this preparation, the branched PEG chains are randomly linked to one of the nine reactive lysine residues of interferon at a 1 : 1 ratio, resulting in nine positional isomers at residues K31, K49, K70, K80, K112, K121, K131, K134 or K164. This modified interferon shows sustained adsorption and reduced renal clearance, resulting in strong antiviral activity throughout a once-weekly dosing schedule. 11, 12 More recently, biochemical procedures were developed to separate the isomers by ion-exchange chromatography. All positional isomers protect MDBK cells against viral infection, however, to a different extent. 13 In addition, the amount of each isomer in the mixture varies from about 5% to more than 30%.
In this study, we compare the biological and receptor affinities of the PEG-IFN variants with the transcriptional activity using DNA microarrays, in order to show whether these processes are linked. In addition, we asked whether the activity of PEG-IFN is the sum or the average of the activity of individual variants. Our data suggest two isomers for further clinical development because their overall activity is superior to the mixture.
RESULTS

The commercial PEG-IFN formulation PEGASYS
s is a mixture of isomers randomly pegylated at single specific lysine residues in the polypeptide chain. Out of 11 possible subtypes, nine, namely K31, K49, K70, K83, K112, K121, K131, K134 and K164, can be detected experimentally by analytical ion-exchange chromatography (Figure 1 ). This preparative two-step chromatography method developed in our laboratory allows isolation of each subtype in sufficient quantity for cell-based interferon response assays. 13 In particular, we were interested whether the intramolecular attachment site of the PEG moiety influences the transcriptional and biological activities. It is further unclear whether the total activity of the commercial formulation represents the sum of the activities of individual isomers, or else is the average of more and less active subspecies.
Biological Activity of the Positional Isomers
The activity of interferon-a is commonly determined by antiviral and antiproliferative assays using responsive cell lines. We first assayed equivalent quantities of the isolated isomers and PEG-IFN as reference, under conditions used for quality control. In general, all positional variants had activity either above (K31, K134) or below (K49, K70, K83, K112, K121 and K131) the PEG-IFN mixture as reference, indicating that the PEG attachment site has an impact on interferon function, which is not surprising for a reaction that requires specific ligand/receptor interaction (Figure 2a) .
One of the hallmarks of interferon signaling is the inhibition of proliferation mediated by the induction of proteins with antiproliferative activity, which transmits the signal to the cell nucleus. For this experiment, we used the human melanoma cell line ME15 as an established experimental system to study the responses to interferon-a. 15 We stimulated triplicate cultures of ME15 overnight with 100 U/ ml of each variant and PEG-IFN as reference. The activity ranking of the isomers showed remarkable similarity to the antiviral assays with K31 and K134 being most inhibitory (Figure 2b) . In both assays, we recovered essentially all the biological activity present in the PEG-IFN mixture (93%) in the individual isomers, which validates the separation procedure (data not shown).
At this point, we had to consider the possibility that the improved activity of the isomers K31 and K134 is due to protein stability rather than being related to receptor signaling. We addressed this question in a time course experiment using a concentration of 500 U/ml of the isomers K31, K134, K121 and, as above, PEG-IFN as reference. If protein stability is involved, we expect a marked activity drop with increasing incubation time, but Figure 1 Typical IEC-HPLC elution profile of separated pegylation isomers from 180 lg PEG-IFN mixture, using an analytical strong cation exchange resin (TOSOH-BIOSEP, SP-5PW, 10 lm particle size, 7.5 mm diameter and 7.5 cm length).
Improved biological and transcriptional activity S Foser et al this was not the case ( Figure 3 ). All isomers tested maintained essentially the activity ranking determined in the previous assays, and K121 had the lowest activity while K31 was most active after 5 days in culture. In a doseresponse experiment, we found that 125 U/ml of K134, for instance, has a similar antiproliferative activity as 500 U/ml of PEG-IFN (data not shown).
The biological data suggest that the specific structural properties of the isomers are responsible for the consistent biological activity ranking in three independent assays. Assuming that transcriptional activation is important to elicit the therapeutic effects of interferons, it is reasonable to assume that the different biological activities are caused by distorted or altered ligand/receptor interaction.
Interaction of the Positional Isomers with a Recombinant IFNR2 Receptor using an Optical Biosensor System We next measured the interaction of the pegylation variants with the IFNR2 receptor immobilized on a sensor chip surface. The ecto domain of IFNR2 (IFNR2-EC) was chosen because of its high binding affinity at 10 nM and its function in signal transduction. The interaction between IFNR1 and IFN is weak (K D 4100 nM) and below the detection sensitivity of the BIAcore system. This technology exploits surface plasmon resonance (SPR) as the detection principle to monitor the label-free interaction between biomolecules in real time. One of the interacting partners, the receptor for instance, is immobilized on the sensor chip surface, while the soluble ligand is floating over the surface at a constant rate, which permits calculation of the binding constants k on and k off . For calibration of the optical biosensor system, preliminary functional tests were necessary. It is essential that the binding affinity is independent of the immobilization technique and the protein, in order to verify the simple kinetic model of 1 : 1 complex formation. We used two different coupling strategies to immobilize IFN or recombinant IFNR2-EC to the sensor chip surface. IFN was covalently attached via free amino groups on a carboxylated dextran sensor surface, and the IFNR2-EC was labeled with biotin and then bound to a streptavidin-coated sensor surface. This strategy allows immobilization of the ligand or the receptor with the other reaction partner in solution and both experimental setups gave consistent rate constants and binding affinities, which validates the assay (data not shown). After successful calibration, we measured the affinity and kinetic constants of the isomers K121, K131, K134 and K164, which represent the full range of biological activity (see above). K31 was not included, because this isomer forms unsoluble aggregates at high protein concentration. To increase the significance of the kinetic and equilibrium parameters, we performed binding studies on the immobilized IFNR2-EC using different concentrations of the isomers with IFN and PEG-IFN as reference. The resulting binding constants for all ligands are summarized in Table 1 . The K D values indicate that the pegylation of IFN causes a PEG position-dependent decrease in the affinity to INFR2-EC, which was somehow expected. Native interferon has the highest affinity and PEG-IFN the lowest, and the The specific inhibition of proliferation (OD490 nm/lg) was determined using the human Me15 melanoma cells stimulated with 100 U/ml of each positional isomer or PEG-IFN, using a commercial assay. The average of three independent biological replicates is shown, and the specific antiproliferative activity of PEG-IFN is marked with a hatched line as reference. Figure 3 Inhibition of cell proliferation of human melanoma cells by PEG-IFN (control) and selected isomers over 5 days. Cells were incubated with 500 U/ml cytokine and the number of living cells was determined every 24 h using a commercial, colorimetric assay. The cell density after 5 days incubation with PEG-IFN was set to 100% as reference. The data represent the average cell density of three independent cell culture replicates. In contrast, the k off constants are more similar and all in the same order of magnitude. Thus, pegylation of interferon clearly reduces IFNR2 receptor affinity and the kinetic rate constant k on , which is usually expected to downmodulate interferon activity. However, based on the biological assays above, the opposite appears to be the case, which reveals a puzzling and uncommon correlation: the lower the affinity, the higher the antiviral activity ( Figure 4 ). This correlation is contradictory to the common drug-screening dogma, where one selects generally for high-affinity compounds, which are usually the most efficient signal transduction molecules.
Transcriptional Response of the Isomers Compared to IFN
We used DNA micorarrays to determine the transcriptional response of human melanoma cells after 48 h stimulation with 100 U/ml of IFN, PEG-IFN or the pegylated isomers. We compared the expression levels of stimulated cells with control cultures using a commercial chip type (U95A; Affymetrix Inc.) containing probe sets for about 11 000 human genes, including all known IFN response genes. The mRNA abundance is expressed as the average difference (AD) between perfect match oligonucleotide probes and a corresponding probe with mismatch in the center position.
To keep the study in a manageable scope, we considered only genes with a change factor of greater than three-fold and 99% reproducibility (P-value o0.01) within three biological replicates. In addition, we included only genes with low activity (ADo20) in the control cultures, which yielded a total of 29 genes upregulated by all interferon formulations. It is not surprising that this group contains mostly known IFN-inducible genes and a subset of these has been associated with the control of proliferation and virus defense, which is consistent with the biological activity of interferon ( Table 2 ). The analysis also shows that the activation of individual genes is isomer specific. For example, the gene encoding the interferon-induced nuclear phosphoprotein (SP110) is preferentially induced by K134 and K70, whereas all other variants induce this gene with similar potency (Table 2) . When the expression data of all genes depicted in Table 2 are displayed graphically, K134 shows higher overall transcriptional activity than the mixture, while K121 appears less active ( Figure 5, panel a) . When the AD values of all genes in Table 2 are added up, a correlation between transcription and biological activity becomes apparent. The isomers K134 and K31 are more active than the PEG-IFN mixture and K121 has the lowest transcriptional activity in this experiment.
These observations indicate that the position of the pegylation site on IFN not only influences the general IFN gene activation but can also affect the induction of individual genes, which is not understood at this point. The transcriptional data suggest and confirm earlier findings in the literature that the biological activity of interferon is linked to gene activation.
DISCUSSION
Purified positional isomers of PEG-IFN were characterized by a combination of biological and molecular assays. We identify here two variants, K31 and K134, with improved properties compared to the commercial formulation. We show a clear relationship between biological and transcriptional activity for all isomers and an inverse correlation between receptor affinity and signal output.
This puzzling correlation is most reasonably explained by the intramolecular position of the polyethyleneglycol side chain in native interferon and altered receptor interaction. The expression level for each gene is given as the mean of the average difference (AD) calculated from three independent biological replicates.
Improved biological and transcriptional activity
S Foser et al 316 The Pharmacogenomics Journal
The key is probably a rather unique signaling mechanism of interferon-a involving two distinct receptors, IFNR1 and IFNR2c.
The IFNR1 receptor exists as a single variant, 16 whereas at least three splice variants of the human IFNR2a have been found. 17 Two forms, IFNR2b and IFNR2c, are membrane anchored and have identical extracellular domains, while IFNR2a is a soluble, secreted protein. 18 Surface expression of full-length IFNR2 is sufficient for binding, but both receptors are required for signal transduction. [19] [20] [21] Mutational studies suggest that IFNR2 has at least three interferon-a-binding sites, at the A helix (residues 12-15), at the AB loop (residues 26-35) and at the E helix (residues 144-153), 22 whereas the IFNR1-binding site was mapped in the vicinity of K121. 23 The affinity of IFN to IFNR2 (K D B10 nM) is at least 10-fold higher than that to IFNR1 (K D 4100 nM), 24 and it is likely that the rather bulky PEG side chains disturb binding or appropriate positioning of the ligand between its receptors. In addition, when IFNR1 and IFNR2 are expressed in murine cells, the affinity of ligand binding increases 10-fold compared with cells expressing only IFNR2. In summary, IFNR1 is required for signal transduction and IFNR2 for high-affinity ligand binding, which results ultimately in the formation of an active signaling complex illustrated in Figure 6 , panel c. When the positional isomers are subdivided into four groups based on activity, it becomes clear that the position of the PEG residue is indeed critical for function. In K31 and K134, the interaction with IFNR1 is not disturbed, although the bulky PEG chains are in close vicinity of the proposed IFNR2-binding site. The contrary configuration exists for the K121 variant, where binding to IFNR1 is apparently distorted. The pegylation sites of the remaining isomers are at intermediate positions and much closer to the IFNR1-binding site than in K134 and K31. Specific and precise contact of the interferon molecule with IFNR1 is apparently necessary for efficient interferon-a signaling, whereas the interaction with IFNR2 is less critical as long as correct positioning to IFNR1 is achieved because the predicted, intramolecular location of the pegylated K31 and K134 residues does not diminish signal transduction through IFNR1. This interaction is, however, disturbed in K83, K112 and K121, where the PEG side chain is in close vicinity of the IFNR1 site. This model is also consistent with the proposed ligand/receptor contact sites found by in vitro mutagenesis. 22, 23 For the practical application of pegylated interferons in the clinic, it might be relevant that the K134 isomer shows Improved biological and transcriptional activity S Foser et al the same antiproliferative activity at 125 U/ml than the commercial mixture at 500 U/ml after 5 days in culture (data not shown). Assuming that this effect translates into improved clinical efficacy, fewer injections of K134 are sufficient for equal therapeutic activity. It remains to be tested whether the isomers K31 and K134 have also improved activity in individuals with natural interferon resistance, which is poorly understood at the molecular level. We are currently analyzing the PEG-isomer-mediated gene expression in a panel of IFN-sensitive and resistant tumor lines, as a first step to address this issue.
In summary, this study provides the basis for the development of a novel generation of pegylated interferon formulations with defined attachment sites, resulting in improved clinical efficacy and better tolerability. The inversed correlation between receptor affinity and output should alert scientists involved in high-throughput screening programs for novel compounds with receptor targets.
MATERIAL AND METHODS
The pegylated interferon a-2a was prepared by the conjugation of lysine e-amino groups at the surface of the interferon molecule with an activated branched polyethylene glycol derivative of a molecular weight of 40 000 Da.
14 The isolation and initial characterization of the isomers of PEGASYS s are described by Foser et al. 13 All other reagents and chemicals were of the highest purity available.
Antiviral Assay
The antiviral activities of the isolated isomers were determined by the reduction of the cytopathic effect of vesicular stomatitis virus (VSV) on Madin-Darby bovine kidney (MDBK) cells. The cell lines were cultured in MEM-medium containing 10% fetal bovine serum. The isomers and PEG-IFN were diluted to a final concentration of 10 ng/ml (assay starting concentration) for the detection of the effective concentration. This effective concentration (EC 50 ) was determined as the concentration needed for 50% protection of the cells against the VSV. In all measurements, the cell culture was challenged with VSV 4 h after addition of the PEG-IFN isomers. After 18 h growth at 371C, the cells were stained with crystal violet s to determine the number of intact cells. The biological activity for the isomers was determined in the antiviral assay, with PEG-IFN as standard reference.
Antiproliferative Activity Assay Cultured human melanoma primary cells (ME-15) were used, because their interferon response is well characterized. 15 The cell line was grown in RPMI medium supplemented with 10% FCS, 2 mM glutamine, 1mM sodium pyruvate, 10 mM nonessential amino acids and HEPES buffer (all from Gibco Life Sciences, UK). The cell proliferation assay was started with approximately 5000-6000 cells per well in a flat-bottom 96-well plate, in the presence or the absence of IFN, PEG-IFN and the isomers over a 5-day period. The number of living cells was then determined using a cell staining kit (Promega, Madison, USA), based on the colorimetric detection of the cleavage of the tetrazolium salt MTS into formazan. The MTS reaction solution was added according to the manufacturer's recommendation for a period of 4 h at 371C; after this period, the absorption at 490 nm was recorded in a spectrophotometer.
Purification of the Recombinant Extracellular Domain of the Interferon Receptor 2 Expressed in E.coli The extracellular domain of the Interferon Receptor 2 (IFNR2-EC) was cloned into a pET15b-vector (Invitrogen, USA) with an N-terminal His-Tag s for expression in E. coli (clone IFNR2-EC), where it is present in inclusion bodies. The cell pellet was resuspended in lysis buffer containing 50 mM Tris, 10% saccharose, 0.02% sodium azide, 10 mM magnesium chloride and EDTA-free protease inhibitor. After the homogenization in a French Press and centrifugation (13 000 r.p.m.), the inclusion bodies were solubilized in 8 M urea. The first chromatography step was a nickel chelate chromatography with a linear gradient from 0 to 500 mM imidazol over 10 column volumes. The pooled peak of IFNR2 was dialyzed against 8 M urea to removal the imidazol. After this dialysis, the sample was diluted to 0.1 A 280 with 8 M urea containing 150 mM Tris/HCL pH 8.0, and stored at room temperature, until the Ellman's assay for sulfhydryl functions was negative. The oxidized IFNR2-EC was dialyzed against 50 mM Tris pH 8.4 for refolding. A volume of 50 mM Tris pH 8.4 was also the starting buffer for the second chromatography. The second chromatography step was with an anion ion-exchange resin (HiTrap Q HP, 5 Â 5 ml, Amersham Biosciences), with a gradient from 0 to 500 mM NaCl.
All purification steps were monitored by SDS-PAGE under reduced and nonreduced conditions. The protein purity was monitored by analytical size-exclusion chromatography using Superdex s 75 and Superdex s 200 HR (PC 3.2/30, Amersham Biosciences). This chromatography method was also used to determine both the binding activity and capacity (data not shown).
BIAcore Assay
The immobilization of the IFNR2-EC was achieved by labeling with biotin, which allows anchoring to a streptavidin sensor surface (SA Sensor, BIAcore).
Biotinylation was performed by diluting the stock protein solution (10 mM acetate, pH 7.5) with HEPES (10 mM, pH¼8.4) to a final protein concentration of 0.23 mg/ml protein (8.65 mM). An 8.65 mM solution of biotinamidocaproate-n-hydroxysuccinimide ester (Fluka) in DMSO was added to the solution to give a final concentration of the biotinylating reagent of 86.5 mM. The mixture was allowed to react for 1 h before it was dialyzed over night against a HEPES buffer (10 mM, pH 8.4, 150 mM NaCl) to remove low molecular weight reaction products. This solution was used in the immobilization procedure. Immobilization was achieved by contacting the solution of the biotinylated protein with the SA sensor surface. The amount of immobilized protein was controlled via the contact time.
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For the binding experiments, 4000 RU, corresponding to approximately 4 ng/mm 2 of protein, were immobilized. Binding experiments were performed in HEPES buffer (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.005% polysorbate 20, pH 7.4) as the running buffer. Interferon solution was prepared by diluting stock solutions of the proteins with running buffer. The flow rate was set to 5 ml/min for all binding experiments. The interferon solutions were contacted for a time interval of 5 min with the immobilized IFNR2-EC.
Calculation of binding data
Dissociation constant (K D ) values were determined by dolfing the time-dependent response curves with a mathematical fit based on the simple kinetic model of a 1/1 complex formation. k on and k off values were obtained from this fit. K D represents the ratio k off /k on .
Oligonucleotide Array Transcript Analysis
The melanoma cell line (ME15) was incubated for 48 h with 100 U/ml of IFN or PEG-IFN samples. After 48 h, the cultured cells were harvested by scraping and the total cellular RNA was extracted with RNA-Beet. From each sample, 10 mg of the total cellular RNA was reverse transcribed (Invitrogen, U.S.A.), labeled (Ambion, U.S.A.), and processed by using commercial kits corresponding to the supplier's instructions. The methods of the alkaline heat fragmentation and the following hybridization of the cDNA with the U95Av2 GeneChip arrays were carried out by the standard procedure provided by the manufacturer of the microchips (Affymetrix, Santa Clara, CA, U.S.A.).
The cell intensity values of the arrays were recorded with a confocal laser scanner (Hewlett Packard, U.S.A.), and data were analyzed using GeneChip v3.1 software (Affymetrix, Santa Clara, CA, U.S.A.). The expression level for each gene was calculated as the normalized average difference of fluorescence intensity, as compared to hybridization to mismatched oligonucleotides, expressed as average difference (AD). Each experiment was performed in triplicate in order to account for biological variation.
The following three criteria were chosen for the selection of differentially expressed genes: (i) The mRNA level values of the treated cells have to be at least three-fold higher compared to the untreated cells. (ii) The signal intensity value in the treated cells must be greater than 50 AD and smaller than 50 AD in the untreated cells. (iii) The standard deviation must be significantly smaller than the absolute change in average difference and the calculated confidence level of a gene was set greater than 99% (P-value o0.01).
